SIDE BY SIDE
Top four on every dimension.
Higher is better. Numbers are tabular, the methodology is on the methodology page, and yes, vendor trust counts because counterfeit risk is real.
SIDE BY SIDE
Top four, head to head
Higher is better. Numbers are tabular, the methodology is on the methodology page, and yes, vendor trust counts because counterfeit risk is real.
ENTIRE DATABASE
Every entry, every dimension
Sortable by score, ranked by composite. Empty cells mean methodology v1.2 capped the score.
| # | COMPOUND | EVIDENCE | MECHANISM | HUMAN DATA | VENDOR TRUST | SAFETY | TOTAL |
|---|---|---|---|---|---|---|---|
| 1 | BPC-157 Body Protection Compound 157 | 7.8 | 8.2 | 4.0 | 6.5 | 7.0 | 6.8 |
| 2 | TB-500 Thymosin Beta-4 fragment | 6.4 | 7.5 | 3.2 | 5.8 | 6.5 | 5.9 |
| 3 | GHK-Cu Copper tripeptide | 8.6 | 8.5 | 6.8 | 8.2 | 8.4 | 8.1 |
| 4 | MOTS-c Mitochondrial Open-Reading-Frame of the 12S rRNA-c | 6.5 | 7.8 | 3.5 | 5.5 | 6.0 | 5.9 |
| 5 | AOD-9604 Anti-Obesity Drug 9604, growth hormone fragment 176-191 | 5.0 | 6.5 | 2.5 | 5.0 | 6.5 | 5.1 |
| 6 | CJC-1295 GRF(1-29) analogue with DAC modification | 5.5 | 7.5 | 3.0 | 4.5 | 5.5 | 5.2 |
| 7 | Ipamorelin GHRP-class growth-hormone secretagogue | 5.5 | 7.0 | 3.0 | 4.5 | 6.0 | 5.2 |
| 8 | Tesamorelin synthetic GHRH analogue (Egrifta) | 8.0 | 8.0 | 7.5 | 7.5 | 7.5 | 7.7 |
| 9 | Sermorelin GHRH(1-29), formerly Geref | 5.5 | 7.0 | 5.0 | 6.0 | 6.5 | 6.0 |